drugset

drugset / Trial / NCT01717248

Safety Study of GCS-100 to Treat Chronic Kidney Disease

NCT01717248 ↗

Phase 1 Completed 29 enrolled La Jolla Pharmaceutical Company

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Timeline

Start: 2013-01
Primary completion: 2013-06
Completion: 2013-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GCS-100	Unknown	—	Other

Indications